
From the U.S. Code Online via GPO Access
[wais.access.gpo.gov]
[Laws in effect as of January 2, 2001]
[Document affected by Public Law 107-107 Section 1044(a)]
[CITE: 10USC2370a]

 
                         TITLE 10--ARMED FORCES
 
                    Subtitle A--General Military Law
 
                PART IV--SERVICE, SUPPLY, AND PROCUREMENT
 
                  CHAPTER 139--RESEARCH AND DEVELOPMENT
 
Sec. 2370a. Medical countermeasures against biowarfare threats: 
        allocation of funding between near-term and other threats
        
    (a) Allocation Between Near-Term and Other Threats.--Of the funds 
appropriated or otherwise made available for any fiscal year for the 
medical component of the Biological Defense Research Program (BDRP) of 
the Department of Defense--
        (1) not more than 80 percent may be obligated and expended for 
    product development, or for research, development, test, or 
    evaluation, of medical countermeasures against near-term validated 
    biowarfare threat agents; and
        (2) not more than 20 percent may be obligated or expended for 
    product development, or for research, development, test, or 
    evaluation, of medical countermeasures against mid-term or far-term 
    validated biowarfare threat agents.

    (b) Definitions.--In this section:
        (1) The term ``validated biowarfare threat agent'' means a 
    biological agent that--
            (A) is named in the biological warfare threat list published 
        by the Defense Intelligence Agency; and
            (B) is identified as a biowarfare threat by the Deputy Chief 
        of Staff of the Army for Intelligence in accordance with Army 
        regulations applicable to intelligence support for the medical 
        component of the Biological Defense Research Program.

        (2) The term ``near-term validated biowarfare threat agent'' 
    means a validated biowarfare threat agent that has been, or is 
    being, developed or produced for weaponization within 5 years, as 
    assessed and determined by the Defense Intelligence Agency.
        (3) The term ``mid-term validated biowarfare threat agent'' 
    means a validated biowarfare threat agent that is an emerging 
    biowarfare threat, is the object of research by a foreign threat 
    country, and will be ready for weaponization in more than 5 years 
    and less than 10 years, as assessed and determined by the Defense 
    Intelligence Agency.
        (4) The term ``far-term validated biowarfare threat agent'' 
    means a validated biowarfare threat agent that is a future 
    biowarfare threat, is the object of research by a foreign threat 
    country, and could be ready for weaponization in more than 10 years 
    and less than 20 years, as assessed and determined by the Defense 
    Intelligence Agency.
        (5) The term ``weaponization'' means incorporation into usable 
    ordnance or other militarily useful means of delivery.

(Added Pub. L. 103-160, div. A, title II, Sec. 214(a), Nov. 30, 1993, 
107 Stat. 1586.)
